# Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients

> **NCT05251727** · PHASE1 · TERMINATED · sponsor: **Veloxis Pharmaceuticals** · enrollment: 77 (actual)

## Conditions studied

- Chemotherapy-induced Peripheral Neuropathy

## Interventions

- **DRUG:** thrombomodulin alfa
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05251727
- **Lead sponsor:** Veloxis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-03-24
- **Primary completion:** 2024-06-05
- **Final completion:** 2024-06-05
- **Target enrollment:** 77 (ACTUAL)
- **Why stopped:** Business Decision
- **Last updated:** 2024-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05251727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05251727, "Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05251727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*